Evidence map›Paper›PMID 41148840›Full record

ArticleCells2025

Ginsenoside Derivative AD-1 Suppresses Pathogenic Phenotypes of Rheumatoid Arthritis Fibroblast-like Synoviocytes by Modulating the PI3K/Akt Signaling Pathway.

Yuan Fu, Fangfang Li, Biao Cui, Zhongyu Zhou, Xizhu Fang, Shengnan Huang, Xingguo Quan, Yuqing Zhao, Dan Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuan FuImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Fangfang LiImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Biao CuiImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Zhongyu ZhouKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, China.
Xizhu FangImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Shengnan HuangImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Xingguo QuanImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.
Yuqing ZhaoKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, China.
Dan JinImmunology Biology Key Laboratory, Yanbian University, Yanji 133002, China.ORCID 0000-0003-0408-4507

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic inflammation of small synovial joints, with frequent extra-articular involvement of the skin and eyes. Prolonged methotrexate therapy for RA is often accompanied by serious side effects. Therefore, new drugs with less toxicity and greater effectiveness need to be developed. The ginsenoside 20(R)-25-methoxyl-dammarane-3β,12β,20-triol (AD-1), purified from

Indexed as

Arthritis, RheumatoidFibroblastsGinsenosidesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionSynoviocytesApoptosisCell MovementCell ProliferationHumansMolecular Docking SimulationMolecular Dynamics SimulationPhenotypeGinsenosidesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktginsenoside derivative AD-1molecular dockingmolecular dynamicsnetwork pharmacologyPI3K/Akt signaling pathwayrheumatoid arthritis

Identifiers

PMID41148840
PMCPMC12564127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.